The involvement of brain-derived neurotrophic factor in 3,4-methylenedioxymethamphetamine-induced place preference and behavioral sensitization

Behav Brain Res. 2017 Jun 30:329:157-165. doi: 10.1016/j.bbr.2017.04.052. Epub 2017 May 1.

Abstract

3,4-Methylenedioxymethamphetamine (MDMA) is known to induce dependence and psychosis in humans. Brain-derived neurotrophic factor (BDNF) is involved in the synaptic plasticity and neurotrophy in midbrain dopaminergic neurons. This study aimed to investigate the role of BDNF in MDMA-induced dependence and psychosis. A single dose of MDMA (10mg/kg) induced BDNF mRNA expression in the prefrontal cortex, nucleus accumbens, and amygdala, but not in the striatum or the hippocampus. However, repeated MDMA administration for 7 days induced BDNF mRNA expression in the striatum and hippocampus. Both precursor and mature BDNF protein expression increased in the nucleus accumbens, mainly in the neurons. Additionally, rapidly increased extracellular serotonin levels and gradually and modestly increased extracellular dopamine levels were noted within the nucleus accumbens of mice after repeated MDMA administration. Dopamine receptor antagonists attenuated the effect of repeated MDMA administration on BDNF mRNA expression in the nucleus accumbens. To examine the role of endogenous BDNF in the behavioral and neurochemical effects of MDMA, we used mice with heterozygous deletions of the BDNF gene. MDMA-induced place preference, behavioral sensitization, and an increase in the levels of extracellular serotonin and dopamine within the nucleus accumbens, were attenuated in BDNF heterozygous knockout mice. These results suggest that BDNF is implicated in MDMA-induced dependence and psychosis by activating the midbrain serotonergic and dopaminergic neurons.

Keywords: 3,4-Methylenedioxymethamphetamine (MDMA); Brain-derived neurotrophic factor (BDNF); Dopamine; Drug dependence; Serotonin.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Behavioral Symptoms / chemically induced*
  • Benzazepines / pharmacology
  • Brain / drug effects*
  • Brain / metabolism
  • Brain-Derived Neurotrophic Factor / genetics
  • Brain-Derived Neurotrophic Factor / metabolism*
  • Conditioning, Operant / drug effects*
  • Dopamine / metabolism
  • Dopamine Antagonists / pharmacology
  • Gene Expression Regulation / drug effects
  • Glial Fibrillary Acidic Protein / metabolism
  • Hallucinogens / toxicity*
  • Locomotion / drug effects
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Microdialysis
  • N-Methyl-3,4-methylenedioxyamphetamine / toxicity*
  • Phosphopyruvate Hydratase / metabolism
  • RNA, Messenger / metabolism
  • Raclopride / pharmacology
  • Serotonin / metabolism

Substances

  • Benzazepines
  • Brain-Derived Neurotrophic Factor
  • Dopamine Antagonists
  • Glial Fibrillary Acidic Protein
  • Hallucinogens
  • RNA, Messenger
  • SCH 23390
  • Serotonin
  • Raclopride
  • Phosphopyruvate Hydratase
  • N-Methyl-3,4-methylenedioxyamphetamine
  • Dopamine